B

BioCryst Pharmaceuticals

Develops oral drugs for rare diseases

Vice President Drug Substance

Full-Time
No salary listed
Expert
PhD
Boston, MA, USA+1 moreMore locations: North Carolina, USA
HybridPrimarily remote, with periodic Boston office work preferred for Boston-area candidates.
Biology & BiotechBioprocess & Biomanufacturing

About the job

Requirements
  • A PhD in chemical engineering, biochemical engineering, biochemistry, chemistry, or a related technical discipline, with substantial relevant industry experience; an equivalent combination of advanced education and experience is also accepted.
  • Typically, 15 or more years of progressive experience in drug substance development, scale-up, technology transfer, and manufacturing, including significant leadership responsibility in an industrial setting.
  • Demonstrated experience leading drug substance programs from early development through late-stage development and commercial readiness. Experience spanning biologics and small-molecule modalities is strongly preferred; deep expertise in at least one modality and demonstrated ability to lead across the other is required.
  • For biologics, strong knowledge of cell line, upstream and downstream process development, scale-up, process characterization, viral safety, comparability, validation, and commercial manufacturing considerations.
  • For small molecules, strong knowledge of active pharmaceutical ingredient route and process development, scale-up, impurity control, solid-state or physical-form considerations, process safety, validation, and commercial manufacturing considerations.
  • Experience providing technical oversight of external development and manufacturing organizations, including partner selection, governance, technology transfer, troubleshooting, performance management, and inspection readiness.
  • Experience preparing, reviewing, or approving drug substance chemistry, manufacturing, and controls content for United States and global regulatory submissions and responding to health-authority questions.
  • Strong knowledge of current good manufacturing practice manufacturing, quality risk management, process validation, change management, comparability, and applicable Food and Drug Administration, European Medicines Agency, International Council for Harmonisation, and other global regulatory expectations.
  • Demonstrated success building and leading teams, developing talent, shaping organizational capabilities, and influencing across a matrixed organization.
  • Ability to translate complex scientific and operational issues into clear strategic choices, risk-based recommendations, and executable plans.
  • Ability to travel domestically and internationally based on business needs.
Responsibilities
  • Own and execute the drug substance strategy across small-molecule active pharmaceutical ingredients and biologic drug substances, from candidate selection and early development through late-stage development, validation, launch readiness, commercialization, and lifecycle management.
  • Align drug substance priorities, deliverables, timelines, budgets, and resources with portfolio and corporate objectives; identify critical dependencies and escalate risks with clear mitigation plans.
  • Create, maintain, and curate the drug substance technology roadmap to guide platform capabilities, process innovation, digitalization strategies, externalization strategy, capacity planning, and investment priorities.
  • Provide drug substance leadership in program teams, portfolio reviews, due diligence, regulatory interactions, indication expansion assessments, and technology or innovation evaluations; collaborate with Analytical Development and Drug Product Development to ensure integrated chemistry, manufacturing, and controls strategies and aligned program execution.
  • Oversee phase-appropriate process development and manufacturing readiness, including biologics cell line and upstream and downstream process development, and small-molecule route, process, and control-strategy development.
  • Provide technical oversight for scale-up, process characterization, process validation readiness, process performance qualification, technology transfer, and manufacturing support. Lead drug substance clinical-supply strategy and execution through pivotal clinical development and collaborate with Manufacturing Science and Technology and Global Manufacturing and Supply after validation to support commercialization, continued process verification, and lifecycle management.
  • Ensure drug substance processes are scientifically sound, reproducible, scalable, cost-conscious, and capable of consistently delivering material with the intended quality profile.
  • Lead technical risk assessments and assess the appropriate level of risk acceptance, mitigation, and contingency planning for significant drug substance issues.
  • Drive timely investigation and resolution of complex process, manufacturing, comparability, raw-material, and supply risks with internal teams and external partners.
  • Provide strategic and operational oversight for drug substance chemistry, manufacturing, and controls content in regulatory submissions and health-authority responses, including Investigational New Drug applications, Investigational Medicinal Product Dossiers, New Drug Applications, Biologics License Applications, Marketing Authorization Applications, and relevant post-approval submissions.
  • Review and approve drug substance development reports, manufacturing and validation documentation, and good manufacturing practice-related submission content for scientific accuracy, consistency, compliance, and suitability for regulatory submission.
  • Partner with other chemistry, manufacturing, and controls functions to establish phase-appropriate development plans, control strategies, comparability approaches, validation strategies, and responses to regulatory questions.
  • Promote compliance with applicable current good manufacturing practice requirements and global regulatory expectations while maintaining a culture of scientific rigor, data integrity, quality risk management, and continuous improvement.
  • Lead the technical evaluation, selection, governance, and performance oversight of contract development and manufacturing organizations and other drug substance partners in collaboration with Manufacturing Science and Technology and Global Manufacturing.
  • Build strategic relationships with external partners to ensure clear accountability, effective knowledge transfer, reliable delivery, inspection readiness, and long-term supply resilience.
  • Ensure technology transfers are appropriately planned, documented, executed, and supported by process knowledge, risk assessments, and fit-for-purpose control strategies.
  • Build, lead, mentor, and develop a high-performing drug substance organization with the capabilities required for the evolving portfolio.
  • Define the future organizational design, talent strategy, and use of internal and external resources for the Drug Substance function.
  • Foster an inclusive, accountable, and collaborative culture that supports sound technical decision-making, effective delegation, and development of scientific and leadership talent.
  • Develop, own, and manage the drug substance operating budget, external manufacturing and development spend, and resource forecasts; ensure disciplined financial performance and transparent trade-off decisions.
  • Represent Drug Substance and, when appropriate, the broader Pharmaceutical Sciences organization in internal governance forums and with external stakeholders.
Desired Qualifications
  • Experience spanning both biologics and small-molecule modalities is strongly preferred.

About the company

B

BioCryst Pharmaceuticals

View

BioCryst Pharmaceuticals develops oral small-molecule drugs aimed at treating rare diseases, with a focus on hereditary angioedema (HAE). The company uses traditional cell biology and medicinal chemistry to design synthetic compounds that target specific protein pathways involved in disease. Its products work as oral therapies that modulate disease-related proteins to reduce symptoms and improve daily functioning, progressing from discovery through clinical trials toward commercialization. BioCryst differentiates itself by concentrating on rare diseases and pursuing oral, non-biologic treatments, leveraging a combined science approach and a patient-focused strategy to bring therapies to market. Its goal is to deliver meaningful, clinically validated treatments that enable patients to engage more fully in everyday activities and improve their quality of life, supported by its drug pipeline and potential licensing opportunities.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Durham, North Carolina

Founded

1986

Get referred to BioCryst Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Japan approved pediatric Orladeyo on August 26, 2026, expanding revenue outside America.
  • Q2 2026 revenue hit $218.3 million, and management raised 2026 guidance to $715 million.
  • CareMed became a national Orladeyo partner on September 8, 2026, widening U.S. access.

What critics are saying

  • Pharvaris plans HAE approval in 2027, threatening Orladeyo pricing and persistence.
  • BioCryst closed Hoover in October 2026, laying off 47 and shrinking discovery capacity.
  • Orladeyo concentration remains existential; one HAE franchise funds BioCryst until navenibart proves itself.

What makes BioCryst Pharmaceuticals unique

  • Orladeyo is the only oral HAE prophylaxis approved for children aged two.
  • BioCryst now commercializes globally through specialty partners like OrphanPacific and CareMed.
  • Management quit internal discovery in 2026, focusing capital on external rare-disease asset acquisitions.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

4%

1 year growth

5%

2 year growth

5%
Associated Press
Oct 21st, 2026
FDA approves BioCryst's Orladeyo oral pellets for adults and adolescents with HAE

BioCryst Pharmaceuticals said the US Food and Drug Administration (FDA) has approved an oral pellet formulation of its once-daily drug ORLADEYO (berotralstat) for adults and adolescents aged 12 and older with hereditary angioedema (HAE). The 150mg pellets prevent HAE attacks. The pellets suit patients who have difficulty swallowing or prefer not to take a capsule. They can be swallowed with water or milk, or sprinkled over a spoonful of soft, non-acidic food. The approval was based on manufacturing data and evidence of the pellets' safety and tolerability compared with capsules. The FDA approved the pellets for children aged 2 to under 12 in December 2025. In two clinical studies, ORLADEYO capsules cut the mean attack rate by 91% at 96 weeks.

Asianet News
Sep 9th, 2026
BCRX stock posts worst day in over 6 months after PHVS trial win in rare swelling disease.

BCRX stock posts worst day in over 6 months after PHVS trial win in rare swelling disease. Published: Sep 09 2026, 05:00 AM IST * FB * TW * Linkdin * Whatsapp * GNFollow Us Pharvaris said on Tuesday its once-daily experimental pill cut monthly swelling attacks by 83% versus a dummy treatment in a late-stage study of hereditary angioedema patients. * BioCryst's Orladeyo is approved to prevent HAE attacks. * Orladeyo sales have continued to grow, and the company is guiding for $625 million to $645 million in revenue from the drug this year. * BioCryst CEO Charlie Gayer said last month that the company wants to buy rare-disease medicines after Orladeyo's success. Shares of BioCryst Pharmaceuticals (BCRX) fell sharply on Tuesday after a competitor reported strong late-stage results in hereditary angioedema, the rare swelling disorder that underpins BioCryst's main product. BCRX fell 9% on Tuesday and clocked its worst day since late February. A rival pill raises the bar. The pressure came from Pharvaris (PHVS), which said its once-daily experimental pill cut monthly swelling attacks by 83% compared with a dummy treatment in a late-stage study. In the two most common forms of the disease, attacks fell by 87%. The medicine was generally well tolerated, and Pharvaris plans to seek approval in the first half of 2027. PHVS shares jumped 7% in regular trading and another 3% after-hours. That market is the same one served by BioCryst's Orladeyo, an approved once-daily capsule used to prevent attacks. Investors marked down Orladeyo on the risk of a stronger oral rival after 2027. Orladeyo market. Orladeyo sales have continued to grow, and the company is guiding for $625 million to $645 million from the drug this year. A pellet version for young children has begun shipping after an earlier manufacturing delay. The drug has generated more than $2 billion in revenue since U.S. approval in 2020. BioCryst is also developing a second hereditary angioedema medicine, navenibart, with late-stage data still expected in 2027. BioCryst CEO Charlie Gayer said last month that the company wants to buy rare-disease medicines after Orladeyo's success. Gayer has said the next products should come from outside deals, not its own lab. Larger drugmakers have been chasing bigger assets. BioCryst is positioning itself as a buyer in the rare-disease gap they leave behind. How did BCRX retail traders react? On Stocktwits, retail sentiment around BCRX rose from 'bearish' to 'neutral' over the past 24 hours, while message volume jumped from 'low' to 'high' levels. A Stocktwits user dismissed Tuesday's selloff, noting that the company already has a real commercial product. "I'm really not worried... it will go up sooner than later... market trying to get rid of the weak hands," they said. View this Stocktwits post Another user opined that no one will switch out of Orladeyo even if Pharvaris's drug gets approved. It also noted that PHVS is valued higher than BCRX despite having no approved products. View this Stocktwits post BCRX stock has gained 16% year-to-date. For updates and corrections, email newsroom[at]stocktwits[dot]com. Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business. 0 Comments / 0 New

The Manila Times
Sep 8th, 2026
CareMed has been selected as a national pharmacy partner by BioCryst and adds Orladeyo(R)(berotralstat) to growing Rare Disease portfolio.

CareMed has been selected as a national pharmacy partner by BioCryst and adds Orladeyo(R)(berotralstat) to growing Rare Disease portfolio. By GlobeNewswire September 9, 2026 NEW HYDE PARK, N.Y., Sept. 08, 2026 (GLOBE NEWSWIRE) - CareMed, an independent specialty pharmacy, has been selected as a pharmacy partner by BioCryst Pharmaceuticals for Orladeyo(R)(berotralstat), a plasma kallikrein inhibitor indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 2 years and older.1 "The addition of Orladeyo reinforces our long-term commitment to supporting rare and complex disease, highlights the strength of our specialty platform in delivering high-touch, patient-centric care across rare, cancer, and orphan disease communities, and further positions us as a trusted partner for patients, providers, and manufacturers," said Benito Fernandez, Chief Commercial Officer. About CareMed Specialty Pharmacy: CareMed is an independent Specialty Pharmacy affiliate of Onco360 and leading clinical support services company. CareMed is committed to bringing together the stakeholders involved in the rare and complex disease treatment process and serve the specialized needs of patients, providers, hospitals, manufacturers, health plans, and payers. CareMed is headquartered in New Hyde Park, New York, and is a specialty pharmacy brand of PharMerica Corporation, a leading institutional pharmacy, specialty infusion, and hospital services company servicing healthcare facilities in the United States. It is accredited through URAC, URAC Rare Disease, ACHC, and NAPB. For more information about CareMed, please visit CareMed.com. Media Contact: Benito Fernandez, Chief Commercial Officer References: 1Orladeyo(R)(berotralstat) [Package Insert]. Durham, NC. BioCryst Pharmaceuticals, Inc. 2025.

BrightSpring Health Services
Sep 8th, 2026
CareMed has been selected as a national pharmacy partner by BioCryst and adds Orladeyo(R)(berotralstat) to growing Rare Disease portfolio.

CareMed has been selected as a national pharmacy partner by BioCryst and adds Orladeyo(R)(berotralstat) to growing Rare Disease portfolio. September 8, 2026 CareMed, an independent specialty pharmacy, has been selected as a pharmacy partner by BioCryst Pharmaceuticals for Orladeyo(R)(berotralstat), a plasma kallikrein inhibitor indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 2 years and older.[1] "The addition of Orladeyo reinforces our long-term commitment to supporting rare and complex disease, highlights the strength of our specialty platform in delivering high-touch, patient-centric care across rare, cancer, and orphan disease communities, and further positions us as a trusted partner for patients, providers, and manufacturers," said Benito Fernandez, Chief Commercial Officer. About CareMed Specialty Pharmacy: CareMed is an independent Specialty Pharmacy affiliate of Onco360 and leading clinical support services company. CareMed is committed to bringing together the stakeholders involved in the rare and complex disease treatment process and serve the specialized needs of patients, providers, hospitals, manufacturers, health plans, and payers. CareMed is headquartered in New Hyde Park, New York, and is a specialty pharmacy brand of PharMerica Corporation, a leading institutional pharmacy, specialty infusion, and hospital services company servicing healthcare facilities in the United States. It is accredited through URAC, URAC Rare Disease, ACHC, and NAPB. For more information about CareMed, please visit CareMed.com. Media Contact Benito Fernandez, Chief Commercial Officer References: [1] Orladeyo(R)(berotralstat) [Package Insert]. Durham, NC. BioCryst Pharmaceuticals, Inc. 2025.

CNBC
Aug 28th, 2026
BioCryst eyes rare disease M&A as Orladeyo hits $645M in 2026 sales

BioCryst Pharmaceuticals is leveraging profits from its hereditary angioedema drug Orladeyo to acquire rare disease treatments. The company expects up to $645 million in 2026 sales from Orladeyo, which has generated over $2 billion since its 2020 FDA approval. CEO Charlie Gayer said BioCryst became profitable last year and aims to maintain profitability whilst expanding beyond being a single-product company. The firm is now seeking external acquisitions rather than internal development, targeting assets with peak sales around $300 million. This shift reflects a broader trend where small and midsize biotech companies are stepping into rare disease drug development as large pharmaceutical firms increasingly focus on multibillion-dollar assets. BioCryst's shares have risen approximately 25% since the start of the year.